Cargando…
RIPK2 as a New Therapeutic Target in Inflammatory Bowel Diseases
Inflammatory bowel diseases (IBDs) are becoming more frequent worldwide. A significant fraction of patients with IBD are refractory to various types of therapeutic biologics and small molecules. Therefore, identification of novel therapeutic targets in IBD is required. Receptor-interacting serine/th...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8079979/ https://www.ncbi.nlm.nih.gov/pubmed/33935757 http://dx.doi.org/10.3389/fphar.2021.650403 |